Sun Pharma Dismisses Speculation Over $12 Billion Organon Deal

Sun Pharmaceutical Industries Limited clarified that a report claiming the company was in the final stages of a $12 billion Organon acquisition is speculative in nature. 

The company detailed its stance in a regulatory filing submitted to exchanges, responding directly to rumour verification communications from both stock exchanges.

The exchanges had sought verification regarding an article published by Moneycontrol captioned, "Sun Pharma slips nearly 4% after $12 billion Organon deal enters final stage," on April 10.

In the official response, Sun Pharmaceutical Industries stated that it possesses no material event or information requiring disclosure under Regulation 30 of the Listing Regulations.